Cargando…

Single-cell RNA-Seq reveals the potential risk of anti-mesothelin CAR T Cell therapy toxicity to different organs in humans

“On-target off-tumor” toxicity is a major challenge to the use of chimeric antigen receptor (CAR)-engineered T cells in the treatment of solid malignancies, because of the expression of target antigens in normal tissues. Mesothelin overexpression is associated with poor prognosis of multiple solid t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Lu, Huang, Yu, Peng, Ling, Zhao, Kaiping, Sun, Yan, Lin, Zhicai, Chen, Yuanyuan, Li, Zhong, Qian, Qijun, Tong, Fan, Zhang, Ruiguang, Dong, Xiaorong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428152/ https://www.ncbi.nlm.nih.gov/pubmed/36059490 http://dx.doi.org/10.3389/fimmu.2022.807915

Ejemplares similares

Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer
por: Zhao, Ruocong, et al.
Publicado: (2021)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

Rapid response in relapsed follicular lymphoma with massive chylous ascites to anti-CD19 CAR T therapy using Piggy Bac: A case report
por: Zhang, Yan, et al.
Publicado: (2022)

The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice
por: Zhang, Qian, et al.
Publicado: (2021)

Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors
por: Zhang, Gui-Zhen, et al.
Publicado: (2019)

Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor
por: Zhang, Zhiwei, et al.
Publicado: (2019)

Correction: Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor
por: Zhang, Zhiwei, et al.
Publicado: (2020)

Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells
por: Jiang, Hua, et al.
Publicado: (2017)

Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells
por: Masoumi, Elham, et al.
Publicado: (2020)

Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer
por: Cao, Bihui, et al.
Publicado: (2021)

Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma
por: Xia, Yuan, et al.
Publicado: (2023)

CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
por: Fischer, Joseph W., et al.
Publicado: (2021)

PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report
por: Li, Chenggong, et al.
Publicado: (2021)

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer
por: Kennedy, Philippa R., et al.
Publicado: (2023)

Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model
por: Wang, Yanan, et al.
Publicado: (2021)

Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells
por: Tokatlian, Talar, et al.
Publicado: (2022)

Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
por: Wang, Zhenguang, et al.
Publicado: (2021)

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin
por: Pang, Nengzhi, et al.
Publicado: (2021)

Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells
por: Feng, Jia, et al.
Publicado: (2022)

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
por: Snell, Daniel, et al.
Publicado: (2023)

Chimeric Antigen Receptor (CAR) Regulatory T-Cells in Solid Organ Transplantation
por: Gille, Ilse, et al.
Publicado: (2022)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Favorable therapeutic response after anti-Mesothelin antibody–drug conjugate treatment requires high expression of Mesothelin in tumor cells
por: Lazzerini, Lea, et al.
Publicado: (2020)

A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
por: Del Bano, Joanie, et al.
Publicado: (2019)

Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies
por: Benloucif, Abdennour, et al.
Publicado: (2023)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells
por: Thomas, Simone, et al.
Publicado: (2023)

CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV
por: Kim, Gloria B., et al.
Publicado: (2019)

The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
por: Yu, Yi, et al.
Publicado: (2011)

Near infrared photoimmunotherapy with an anti-mesothelin antibody
por: Nagaya, Tadanobu, et al.
Publicado: (2016)

Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells
por: Davey, Brianna C., et al.
Publicado: (2022)

CAR T Cell Therapy for Neuroblastoma
por: Richards, Rebecca M., et al.
Publicado: (2018)

Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma
por: Liu, Zhenjiang, et al.
Publicado: (2017)

Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of “On-Target, Off-Tumor Toxicity”
por: Zhang, Yinyin, et al.
Publicado: (2021)

Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas
por: Zuo, Pengcheng, et al.
Publicado: (2023)

An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer
por: Wittwer, Nicole L, et al.
Publicado: (2023)

Integration of scRNA-Seq and bulk RNA-Seq uncover perturbed immune cell types and pathways of Kawasaki disease
por: Cao, Naixin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sacavkel52npraap5bequco51f